Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma.
OBJECTIVE
Approximately 50% of all malignant prostatic tumors contain neuroendocrine cells, which cannot be attributed to small cell prostatic carcinoma or carcinoid-like tumors, and which represent only 1 to 2% of all prostatic malignancies. Only limited data are available concerning the plasma levels of neuroendocrine markers in patients with prostatic tumors. Therefore, we determine the incidence of high plasma levels of neuroendocrine markers in patients with benign and malignant prostatic disease.


METHODS
The presence of elevated plasma neuropeptide levels was investigated in 135 patients with prostatic carcinoma and 28 with benign prostatic hyperplasia. Plasma chromogranin A, neurone-specific enolase, substance P, calcitonin, somatostatin, neurotensin and bombesin levels were analyzed by immunoassays, and were compared to clinical and pathological stages of disease. Plasma prostatic acid phosphatase and prostate specific antigen levels were also determined. All patients were followed for at least 2 years after inclusion in the study.


RESULTS
Significantly elevated levels of chromogranin A were detected in 15% of patients with prostatic carcinoma before any treatment. During hormone resistant prostate cancer progression plasma chromogranin A and neuron-specific enolase levels were elevated in 55% and 30% of the patients, respectively. In patients with stage D3 disease survival curves were generated by the Kaplan-Meier method, and log rank analysis revealed a statistically significant difference between groups positive and negative for chromogranin A. Substance P and bombesin were also occasionally elevated in prostatic tumors. Determination of neuroendocrine differentiation by neuron-specific enolase or chromogranin A immunoassays was not helpful in the prediction of progressive localized prostatic carcinoma.


CONCLUSIONS
Future studies of plasma neuropeptide levels should confirm whether these parameters can be used as prognostic markers during late progression of prostatic carcinoma or for the selection of patients suitable for evaluation of new antineoplastic drugs to be active against neuroendocrine tumors.
Cussenot
O
O
Departments of Urology, Hormone Biology, and Pathology, Hôpital Saint Louis, Paris, France.
Villette
J M
JM
Valeri
A
A
Cariou
G
G
Desgrandchamps
F
F
Cortesse
A
A
Meria
P
P
Teillac
P
P
Fiet
J
J
Le Duc
A
A
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001839:Bombesin / Q000097:blood; D002116:Calcitonin / Q000097:blood; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood; D006801:Humans; D007118:Immunoassay; D008297:Male; D008875:Middle Aged; D009479:Neuropeptides / Q000097:blood*; D009496:Neurotensin / Q000097:blood; D010751:Phosphopyruvate Hydratase / Q000097:blood; D011379:Prognosis; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood* / Q000401:mortality; D013004:Somatostatin / Q000097:blood; D013373:Substance P / Q000097:blood; D015996:Survival Rate
D014408:Biomarkers, Tumor; D053379:Chromogranin A; D002864:Chromogranins; D009479:Neuropeptides; D013373:Substance P; D009496:Neurotensin; D013004:Somatostatin; D002116:Calcitonin; D000135:Acid Phosphatase; D017430:Prostate-Specific Antigen; D010751:Phosphopyruvate Hydratase; D001839:Bombesin